NCT02211170View on ClinicalTrials.gov

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

April 30, 2000

Conditions
Healthy
Interventions
DRUG

BIBR 796 BS, low dose

DRUG

BIBR 796 BS, high dose

DRUG

Placebo

DRUG

Lipopolysaccharide

Lipopolysaccharide (LPS) for endotoxin challenge

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY